Loading...
BNTX logo
BNTX
BioNTech

Advanced mRNA And Oncology Programs Will Unlock Global Healthcare Demand

Published
13 Apr 25
Updated
07 May 25
AnalystHighTarget's Fair Value
US$169.93
43.1% undervalued intrinsic discount
10 Sep
US$96.74
Loading
1Y
-21.6%
7D
-14.0%

Author's Valuation

US$169.9

43.1% undervalued intrinsic discount

AnalystHighTarget Fair Value

Narrative
Updates4

Shared on07 May 25
Fair value Increased 11%

Read more

Shared on30 Apr 25
Fair value Decreased 1.07%

AnalystHighTarget made no meaningful changes to valuation assumptions.

Read more

Shared on23 Apr 25
Fair value Increased 9.72%

AnalystHighTarget made no meaningful changes to valuation assumptions.

Read more

Shared on16 Apr 25
Fair value Decreased 18%

AnalystHighTarget made no meaningful changes to valuation assumptions.

Read more